PUBLISHER: Grand View Research | PRODUCT CODE: 2017714
PUBLISHER: Grand View Research | PRODUCT CODE: 2017714
The global pet medicine market size was estimated at USD 14.5 billion in 2025 and is projected to reach USD 32.8 billion by 2033, growing at a CAGR of 10.9% from 2026 to 2033. The industry is growing due to rising chronic diseases in dogs and cats, expansion of vaccination and preventive care programs, innovation in veterinary therapeutics and biologics, and increasing funding for companion animal research.
A key driver for the market is rapid innovation in veterinary therapeutics and biologics that is expanding treatment options for chronic and complex diseases in companion animals. Pharmaceutical companies and veterinary research groups are introducing advanced therapies that mirror innovations seen in human medicine, which is increasing clinical adoption and improving treatment outcomes for pets. One such instance is the February 2026 approval of Merck & Co.'s NUMELVI (atinvicitinib tablets) by the FDA; this product is used for dogs suffering from allergic dermatitis. The therapy is a second-generation Janus kinase (JAK) inhibitor designed to control pruritus associated with allergic skin diseases in dogs. The product received approval from the FDA and is the first veterinary therapy in its class, providing once-daily treatment that directly targets inflammatory cytokine pathways responsible for itching and skin inflammation.
Biologic therapies are also gaining traction in pet medicine. Companies such as Zoetis are investing in monoclonal antibody research for animals. These therapies are designed to target specific disease pathways with high precision and have already been used to manage conditions such as chronic pain and inflammatory disorders in companion animals. Their mechanism of action resembles biologic treatments widely used in human medicine, which highlights the convergence of human and veterinary drug innovation. Another area of rapid advancement is regenerative medicine. Veterinary researchers are increasingly exploring stem cell therapy for pets to treat degenerative conditions such as osteoarthritis and orthopedic injuries. These therapies involve collecting and processing stem cells from the animal and reintroducing them into damaged tissues to promote healing and tissue regeneration. Veterinary clinics are testing these treatments as alternatives to invasive surgery or long-term medication in dogs and cats.
Precision medicine and immunotherapy are also emerging as high-growth areas. Research initiatives are studying targeted immune therapies and genomic approaches to treat diseases such as cancer in companion animals. These programs aim to personalize treatment strategies based on genetic or molecular disease profiles, which can improve treatment success rates and reduce adverse effects. To conclude, advances in biologics, regenerative medicine, and targeted pharmaceuticals are reshaping the pet medicine sector. These innovations are expanding the therapeutic pipeline and driving higher demand for advanced veterinary treatments.
Global Pet Medicine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pet medicine market report based on product, pet, route of administration, distribution channel, drug type, and region.